Life Science News

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor …

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome.
As quoted in the press release:

“The patent scheduled to issue from this application should result in additional intellectual property protection for RECORLEV, potentially extending our drug candidate’s patent term beyond orphan drug exclusivity and enhancing the overall RECORLEV patent portfolio,” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma. “This marks an important step in our ongoing efforts to optimize the value of RECORLEV and further strengthens Strongbridge’s leadership position in rare endocrine disease,” Pauls added.

Click here to read the full press release.

MARKETS

Markets
TSX18729.66-104.50
TSXV602.35-13.59
DOW31037.68+69.86
S&P 5003845.08+13.69
NASD11361.85+39.61
ASX6629.30+16.70

COMMODITIES

Commodities
Gold1740.12-28.75
Silver19.19-0.03
Copper3.44+0.03
Palladium1923.51-4.50
Platinum857.00-8.00
Oil98.29-0.24
Heating Oil3.43+0.02
Natural Gas5.53+0.02

DOWNLOAD FREE REPORTS

×